You are in: eMedicine Specialties > Otolaryngology and Facial Plastic Surgery > INNER EAR Cochlear Implants, Surgical TechniqueArticle Last Updated: Sep 3, 2008AUTHOR AND EDITOR INFORMATIONAuthor: Cliff A Megerian, MD, FACS, Medical Director of Adult and Pediatric Cochlear Implant Program, Vice-Chairman and Director of Otology and Neurotology, University Hospitals of Cleveland; Professor, Department of Otolaryngology-Head and Neck Surgery and Neurological Surgery, Case Western Reserve University School of Medicine Cliff A Megerian is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Neurotology Society, American Otological Society, Association for Research in Otolaryngology, Massachusetts Medical Society, Society for Neuroscience, Society of University Otolaryngologists-Head and Neck Surgeons, and Triological Society Coauthor(s): Gail S Murray, PhD, MEd, Clinical Director, Cochlear Implant Program, Director, Department of Audiology Services, University Hospitals of Cleveland, Rainbow Babies, and Children's Hospital of Cleveland Editors: Robert A Battista, MD, FACS, Assistant Professor of Otolaryngology, Northwestern University Medical School; Physician, Ear Institute of Chicago, LLC; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Gerard J Gianoli, MD, Clinical Associate Professor, Department of Otolaryngology-Head and Neck Surgery, Tulane University School of Medicine; Vice President, The Ear and Balance Institute; Chief Executive Officer, Ponchartrain Surgery Center; Christopher L Slack, MD, Otolaryngology-Facial Plastic Surgery, Private Practice, Associated Coastal ENT; Medical Director, Treasure Coast Sleep Disorders; Arlen D Meyers, MD, MBA, Professor, Department of Otolaryngology-Head and Neck Surgery, University of Colorado School of Medicine Author and Editor Disclosure Synonyms and related keywords: cochlear implants, cochlear implant, cochlear implant surgery, cochlear implantation, cochlear hearing implant, cochlear, hearing implants, implants, hearing aids, sensorineural hearing loss, hearing loss, severe-to-profound hearing loss, profound hearing loss, severe hearing loss, cochlea, cochlear implant center INTRODUCTIONCochlear implantation has become a routine procedure in the The team concept in cochlear implant evaluation allows for an exchange of information between the surgeon and other members of the implant and rehabilitation process, including audiologists, speech and language therapists, social workers, and psychologists. Typically, the patient is referred to a cochlear implant center, and initial contact is made. The patient may first be seen and identified as an implant candidate by an audiologist. Hence, a patient can enter the evaluation process in a number of different ways. Nonetheless, various issues are taken into consideration, including medical aspects of the patient's history, the audiologic evaluation, and radiographic studies. Although the team evaluation concept is explained at greater length in the Indications section, it is notable because it allows for proper selection of patients, the continuous flow of pertinent dialogue, and the promotion of realistic expectations on the part of the patient and the patient's family. Typically, the audiologist measures the patient's hearing with and without hearing aids. Evaluation with pure-tone audiometry and auditory brainstem response (ABR) testing (in the case of children) is often performed. Otoacoustic emission (OAE) testing complements these studies; OAE results often indicate the need for a trial of newer and sometimes stronger hearing aids. History of the ProcedureIn 1957, Djourno and Eyries made the observation that activation of the auditory nerve with an electrified device provides auditory stimulation in a patient. This observation is considered the seminal observation that paved the way for modern cochlear implantation. In 1963, Doyle and Doyle's early experiments in scala tympani implantation preceded the first House/3M single-channel implant in 1972.1 Multichannel devices introduced in 1984 have replaced single-channel devices by virtue of improved speech recognition capabilities. As of 2006, nearly 100,000 cochlear implants are estimated to have been performed worldwide, and approximately 6,000 procedures take place annually in the ProblemSevere-to-profound hearing loss, as evidenced by the lack of useful benefit from hearing aids, often determines one's candidacy for cochlear implantation. In children, this is confirmed via auditory testing and failure to develop basic auditory skills. In adults, candidates should receive limited or no benefit from appropriate hearing aids (ie, a score of 50% or less on sentence recognition tests in the best-aided listening situation). FrequencyThe incidence of congenital hearing loss varies by study. Niparko reviewed studies from the 1980s and 1990s and noted that one of the most carefully performed epidemiologic studies was that of Van Naarden et al, which noted an overall prevalence rate of serious hearing impairment of 1.1 cases per 1000 children aged 3-10 years.2 By age 75 years, 360 of 1000 adults have a disabling hearing loss. According to the 1996 National Institute on Deafness and Other Communications Disorders survey, more than 28 million Americans are deaf or hearing impaired.3 This statistic may reach 40 million by the year 2020. EtiologyCommon etiologies of deafness that lead to consideration of cochlear implantation in pediatric patients include idiopathic, genetic, and acquired causes that result in congenital and delayed-onset hearing loss. Genetic hearing loss can be dominant or recessive. Infectious etiologies, including bacterial and postviral meningitis, can lead to severe hearing loss. Meningitis-related deafness has decreased with the routine use of the Haemophilus influenzae vaccine in children. Adult patients presenting for implantation include those with progressive hearing loss that began in childhood, viral-induced sudden hearing loss, ototoxicity, otosclerosis, Ménière disease, trauma, autoimmune conditions, presbycusis, and bacterial infections. PathophysiologyTypically, patients presenting with severe-to-profound deafness have had a direct or indirect injury to the organ of Corti, leading to degeneration or dysfunction of the hair cell system. Therefore, success of cochlear implantation depends on stimulation of surviving spiral ganglion neurons. The number of surviving neuron populations needed for successful implantation remains unclear. In 1991, Linthicum et al reported successful speech understanding in a patient who demonstrated less than 10% of the normal complement of neurons via a temporal bone study.4 Therefore, despite the wide range of surviving neurons present in various pathologic causes of deafness (10-70% of the normal 35,000-40,000 cells), most patients are likely potential implant candidates. ClinicalIn the past, children with hearing loss presented to the physician after their parents developed a concern about their child's lack of response to noise and voices. This may have brought the child to the attention of an otolaryngologist promptly (within a few weeks to months), or consultation may have been delayed up to a number of years. With the addition of universal infant screening, babies are identified at birth as having a hearing loss. The loss is confirmed and quantified with auditory brainstem testing, and, if profound, the patient is referred for cochlear implant evaluation. Children are fitted with hearing aids, and a decision to implant is based on progress or lack of language development and careful counseling of the family. If a child is clearly found to be an implant candidate, an earlier implantation results in superior hearing and speech outcomes. For excellent patient education resources, visit eMedicine's Ear, Nose, and Throat Center. Also, see eMedicine's patient education article Hearing Loss, as well as the eMedicine article. INDICATIONSThe main indication for cochlear implantation is severe-to-profound hearing loss that is not adequately treated with standard hearing aids. The clinical conditions that lead to such an indication include various scenarios, as follows:
Generally, the candidacy for implantation is considered separately for adults and children. As outlined in the 1995 National Institutes of Health (NIH) consensus statement on cochlear implantation, adult candidacy is noted as being successful in postlingually deaf adults with severe-to-profound hearing loss with no speech perception benefit from hearing aids.5 In addition, the statement notes that "most marginally successful hearing aid users implanted with a cochlear implant will have improved speech perception performance." Medicare guidelines as of January 2005 allow for cochlear implantation in patients with 50% aided sentence discrimination scores and allow for 60% sentence scores in clinical trials. Clearly, the trend over time is that relaxed guidelines are better, and better cochlear implant performance and outcome have been demonstrated. Prelingually deafened adults, although potentially suitable for cochlear implantation, must be counseled in regard to realistic expectations, as language and open-set speech discrimination outcomes are less predictable. A strong desire for oral communication is paramount for this group of patients Children are considered candidates for cochlear implantation at age 12 months, and, because of meningitis-related deafness with progressive cochlear ossification, occasional earlier implantation is necessary. Investigations are ongoing into extending the age of early routine implantation to younger than 12 months. Audiologic criteria include severe-to-profound sensorineural hearing loss bilaterally and poor speech perception under best-aided conditions, with a failure to progress with hearing aids and an educational environment that stresses oral communication. The use of objective testing in this age group includes auditory brainstem response (ABR) testing and otoacoustic emission (OAE) testing in addition to trials of various auditory training programs, which are essential before cochlear implantation. For further discussion, see the eMedicine article Cochlear Implants, Indications. RELEVANT ANATOMYThe surgeon performing cochlear implant surgery must be experienced in otologic surgery and, ideally, some aspects of neurotologic surgery. Intimate knowledge of the relevant surgical anatomy of the mastoid cortex, retromastoid region, and posterior/middle cranial fossa dura is important in properly performing the approach to the facial recess and in properly creating an implant receiver well that provides low-profile placement of the internal device. CONTRAINDICATIONSContraindications to cochlear implantation may include deafness due to lesions of the eighth cranial nerve or brain stem. In addition, chronic infections of the middle ear and mastoid cavity or tympanic membrane perforation can be contraindications. The absence of cochlear development as demonstrated on CT scans remains an absolute contraindication. Certain medical conditions that preclude cochlear implant surgery (eg, specific hematologic, pulmonary, and cardiac conditions) also may be contraindications. The lack of realistic expectations regarding the benefits of cochlear implantation and/or a lack of strong desire to develop enhanced oral communication skills poses a strong contraindication for implant surgery. WORKUPLab Studies
Imaging Studies
TREATMENTMedical therapyIn the context of this article, any medically available treatments for sudden or progressive sensorineural hearing loss are assumed to have been exhausted. In addition, standard modes of amplification are assumed to have been deemed by the patient and clinician to provide unsatisfactory levels of hearing and speech discrimination. Surgical therapyThe implant evaluation and workup can seem time consuming and cumbersome to some patients. Accurately assessing candidacy from an audiologic, medical, and emotional standpoint is necessary. In addition, with the various cochlear implant options available, the patient often spends much time and thought on choosing the most appropriate implant. Preoperative detailsIn addition to the otoneurologic examination, pediatric and adult patients are cleared through their primary medical physician for suitability for general anesthesia. Determine the side of the cochlear implant. Cochlear implant manufacturers no longer make side-specific implants (eg, early generation Clarion); however, a frank preoperative discussion between the surgeon and recipient should include a suggestion and agreement of the ear to be implanted. On the day of surgery, the operative ear is marked in the preoperative holding area. A patient who still uses a hearing aid is allowed to take the hearing aid into the operating room, and it is removed after anesthesia is induced. The hearing aid is returned to the patient postoperatively. In certain circumstances, a sign language interpreter accompanies the patient into the holding area and operating room to assist with anesthesia induction. Nurses can facilitate patient comfort by communicating on a small writing board. Upon entering the operating room, the operating surgeon and the nursing team again confirm the correct side of surgery. Intravenous prophylactic antibiotics are routinely given and the facial nerve monitor is applied. Intraoperative detailsStep 1 - Flap marking and incision design (see Image 1) Once the patient is properly anesthetized, the postauricular crease is infiltrated with 1% lidocaine with 1/100,000 epinephrine. At the authors' center, minimal to no hair is shaved. In order to establish where the cochlear implant receiver will lie, an imaginary line is drawn through the lateral canthus of the eye through the external canal and posteriorly into the retromastoid region. Then, the surgeon visualizes a nearly perpendicular line that travels along the postauricular area tangential to the line at which the helix touches the retroauricular region. The posterior-superior quadrant marked out by the angle created by these intersecting lines is the region in which the implant receiver well should be drilled. Because all 3 commercially available FDA-approved multichannel cochlear implant devices have a behind-the-ear (BTE) processor, room for a BTE device should be taken into account; hence, a mock-up of a BTE may be helpful. The incision that is now standard in the authors' center, as well as in many others, is a line along the postauricular crease, with little or no extension superior to the hair-bearing area. After making an incision and carrying it down to the level of the temporalis fascia superiorly and to the level of the mastoid periosteum, develop anterior and posterior supraperiosteal flaps. Anteriorly raise an anteriorly based periosteal flap, including temporalis fascia, until the spine of Henle is identified. Using a mock-up of the implant receiver, mark the position along the mastoid region for the cochlear implant and leave room for a BTE processor. Mark this spot with methylene blue before the incision or with a marking pen directly on bone after the periosteal flap is raised. Attention then is turned to the mastoidectomy. Step 2 - Mastoidectomy and posterior tympanotomy (see Image 2) Using a large (6-mm) cutting burr, suction irrigation, and a high-powered microscope, perform a mastoidectomy with care taken to avoid the standard saucerization and skeletonization of the sinodural angle, tegmen mastoideum, and sigmoid sinus. Leaving bone over these areas is important to allow retention of the implant array leads. Thin the bony posterior canal and open the antrum and identify the horizontal semicircular canal. Using a 3-mm cutting burr, thin the canal wall further and identify the incus. With a 2-mm diamond burr, skeletonize the facial nerve in its descending portion, identify the chorda tympani, and begin the posterior tympanotomy. Open the facial recess widely with the 2-mm diamond burr and copious suction irrigation, with care taken to leave bone over the facial nerve. As the recess is opened, identify the stapedial tendon and stapes suprastructure. Then, identify the round window niche inferiorly. If visualizing the round window is difficult, remove bone anteriorly and medially to the facial nerve with the diamond burr and rotate (airplane) the patient's bed toward the surgeon to allow for visualization of the round window. In some circumstances of poor round-window visualization, an extended facial recess approach, which requires sacrifice of the chorda tympani at its inferior-most region, may be helpful. Again, take care to avoid any injury to the tympanic membrane, which is just lateral to the chorda tympani. Thoroughly irrigate the wound, and identify and confirm clear visualization and accessibility of the round window membrane. Then, turn attention to the site of the receiver well. Step 3 - Cochlear implant receiver well drill out with tie-down holes (see Image 3) Once the mastoidectomy has been completed, place a surgical mock-up of the implant and identify the position for the drilling of the well, usually posterior and superior to the mastoidectomy site. In children, the skull typically is not thick enough to reliably achieve a depth that allows full cochlear implant placement; therefore, a dural island may be created. Using a marking pen, outline the mock-up and drill out the well to skeletonize the bone down to the level of the dura. Step 4 - Cochleostomy (see Image 4) The recommendations for cochleostomy size given by a number of different cochlear implant manufactures vary. Regardless of the type of implant, the author uses a small cochleostomy, which is performed 1 mm inferior and posterior to the stapes suprastructure on the cochlear promontory. This is performed with a 1-mm diamond burr. Once the basilar turn is visualized, any bone from ossification can be drilled out and further removed with stapes picks. Take care to use irrigation and suction to avoid thermal injury to the facial nerve. The rotating shaft of the drill is always kept away from the facial nerve. Facial nerve monitoring is routinely used and is helpful in circumstances in which variations of normal facial nerve anatomy are present. In addition, from a patient and surgeon's comfort perspective and for medicolegal reasons, using the facial nerve monitor in routine cases is wise. Step 5 - Implant tie down and electrode insertion (see Image 5) Once the cochleostomy has been achieved satisfactorily, the wound is irrigated again. Bring the cochlear implant into the field only after ensuring that no further cauterization with electrocautery is necessary. Then, secure the cochlear implant within the well and tie it down. If the Clarion device is used, an inserter tool then can facilitate the insertion of the implant. Use a temporalis fascia graft to pack the cochleostomy site. Using the Nucleus 24 Freedom device, the cochlear implant array is held with toothless forceps and introduced partially into the scala tympani. At this point, the off-stylet introduction technique is performed, and the stylet is removed. If resistance is met, consider reinspecting the basilar turn of the cochlea for ossification and/or open the cochleostomy further prior to removal of the stylet. If the Clarion device is used, carefully reload the insertion tool and, in both cases, avoid forcing a cochlear implant when resistance is met. Be careful not to injure or inadvertently bend the electrode array at this time. Partial insertion is sometimes necessary. Then, secure the cochlear implant within the well, and tuck the silastic receiver portion of the device under a temporalis or pericranial flap. Secure the electrode lead within the mastoidectomy defect. Gel foam may be used to secure the lead within the drilled-out trough in between the well and the mastoidectomy site and may be used to help secure lead 1 of the Nucleus 24 device, which is tucked under the temporalis fascia. With most commercially available multichannel cochlear implant devices, make plans for impedance testing and neural-response telemetry (NRT) before closure. Step 6 - Telemetry, closure, and radiograph (see Image 6) Place the skin flap back over the cochlear implant device. Using an intraoperative sterile telemetry device, perform impedance testing for implant integrity. For MED-EL, Clarion, and Nucleus systems, impedance testing and NRT is routinely performed. After confirming the integrity of the electrodes, initiate closure. Typically, the periosteal flap is closed over the mastoidectomy site and the cochlear implant with absorbable sutures. Return and close the skin flap with subcutaneous interrupted sutures and a running subcutaneous-subcuticular absorbable suture. Place Steri-Strips with a tincture of benzoin; also place a mastoid dressing. Anteroposterior plain films can be obtained at this point to document intracochlear placement of the electrode array. Awaken and extubate the patient; then, return the patient to the recovery room. Prior to discharging the patient from same-day surgery, the audiology team meets with the family, provides cochlear implant documents, and makes plans for initial stimulation and mapping, which takes place 3-5 weeks postoperatively. Postoperative detailsPatients are typically returned to the recovery room with orders for antinausea medication. Most patients have minimal nausea and vertigo because routine intraoperative administration of dexamethasone (Decadron) has a prophylactic effect on postoperative nausea. Most patients have minimal dizziness or gait issues and are able to be discharged an hour and a half following surgery. Follow-upSend patients home with their mastoid dressing intact and 7 days of an oral antibiotic and pain medication. Provide follow-up care in 2-3 days to remove the mastoid dressing. Many patients now simply remove their mastoid dressing at home on postoperative day 2 and are instructed to inspect the wound for bleeding or hematoma. Schedule a second visit at 2 weeks postoperative, and schedule plans for device stimulation 3-5 weeks following the initial surgery. COMPLICATIONSThe risks of cochlear implantation mimic those of mastoidectomy. These include postoperative infection, facial paralysis, cerebrospinal fluid (CSF) leakage, and meningitis. Manage these risks via standard techniques. In 2002, the risk of meningitis was approximately 1 in 1000 cases and likely related to either the size of the cochleostomy or the design of the Clarion device with implant positioner. Clarion withdrew the positioner, and analyses of non—positioner-related cases of meningitis revealed that the risk of meningitis in these patients was similar to that of a nonimplanted deaf patient. To minimize the risk of meningitis, the Centers for Disease Control and Prevention (CDC) has recommended all patients have up-to-date immunizations to Streptococcus and Haemophilus. The risk of meningitis in a patient who has received an implant with a positioner persists for at least 2 years postimplantation, so a high index of suspicion is indicated for these patients, as well as verification of proper immunization. Patients should be aware that any residual hearing in the operated ear is lost after implantation. Complications specific to cochlear implantation include flap dehiscence, seroma formation, implant migration, facial nerve stimulation, perilymphatic or CSF gusher, and device failure. The FDA maintains a Web site (MAUDE) dedicated to tracking individual implant complications. As this database develops, the consumer can more easily gain access to useful real-time information that pertains to individual manufacturer or device quality. Flap complications can be avoided by using an incision that does not compromise the blood supply to the postauricular region, such as the one outlined in the Intraoperative details section. Seroma formation may be avoided by use of a mastoid compressive dressing for at least 2 days. If a seroma develops, it can be evacuated using an 18-gauge or larger needle using sterile technique. A mastoid dressing should be reapplied for 2 days. Initially raising a supraperiosteal flap and then raising a subperiosteal and pericranial flap based in opposite directions results in complete coverage of the internal receiver with fascia, which creates a secure closure that minimizes postoperative complications. Promptly treat minor infections with oral and topical antibiotics. Intravenous antibiotics and, if necessary, flap revision can save an otherwise extruding device secondary to major infection. Implant migration can be avoided by securing the device deep within the bony well with secure tie-down sutures. Electrode migration is minimized by packing the cochleostomy with tissue such as temporalis fascia or muscle. Facial stimulation usually can be managed by deactivating certain offending electrodes. OUTCOME AND PROGNOSISThe overall prognosis for hearing improvement and improved quality of life in the properly selected patient is excellent. Patient selection is addressed in Indications. FUTURE AND CONTROVERSIESCochlear ossification results from inflammation of the inner ear, often following deafness secondary to meningitis. Most instances of ossification do not preclude cochlear implantation because total ossification is rare. In one series, bony growth was confined to the basal-most portion of the cochlea and was easily traversed with minimal drilling. Electrode insertion was complete in 14 of 15 patients in the series. The future of cochlear implantation is exciting and is now upon us. Bilateral cochlear implantation has demonstrated significant benefits for patients in a number of areas, which include hearing in noise, speech perception outcomes, and sound directionality. Audiologists, otolaryngologists, and pediatricians have known for years that the standard of care for children is binaural hearing (2 hearing aids) habilitation for hearing aid–serviceable hearing disorders. Now, the norm is rapidly becoming parents and clinicians who offer binaural cochlear implantation to maximize hearing and speech outcomes in both children and adults. The concept of implanting patients with residual hearing in the low frequencies has led to the development of short implants, which contact the basal or high frequency portion of the cochlea while leaving the low frequency (apex) undisturbed.7 Clinical trials are underway in order to determine the feasibility of such an approach. In the future, patients can expect faster and better coding strategies, which result in better speech perception. In addition, the improvement in chip design and battery design will likely pave the way for totally implantable cochlear implants as microphones become integrated to middle- or external-ear structures. Nanotechnology is rapidly providing hope for smaller, more robust, electrode array designs with a virtually endless number of electrode contact sites. These advances will likely continue to lead to a lowering of candidacy thresholds and improved performance. MULTIMEDIA
REFERENCES
Cochlear Implants, Surgical Technique excerpt Article Last Updated: Sep 3, 2008 | ||||||||||||||||||||||||||||||||||||||||||